Denne overordnede sikkerhedsprofil forblev ens for 107 patienter behandlet med CRIXIVAN alene eller i kombinationsbehandling i op til 48 uger.
This overall safety profile remained similar for 107 patients treated with CRIXIVAN alone or in combination for up to 48 weeks.